UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-Q
QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY
Investment Company Act file number 811-03595
Name of Fund: BlackRock Healthcare Fund, Inc.
Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809
Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Healthcare Fund, Inc., 55 East 52nd Street, New York, NY 10055
Registrant’s telephone number, including area code: (800) 441-7762
Date of fiscal year end: 04/30/2012
Date of reporting period: 07/31/2011
Item 1 – Schedule of Investments
|
|
|
|
Schedule of Investments July 31, 2011 (Unaudited) |
BlackRock Healthcare Fund, Inc. |
|
(Percentages shown are based on Net Assets) |
|
|
|
|
|
|
|
|
Common Stocks |
|
Shares |
|
Value |
|
||
Biotechnology 14.2% |
|
|
|
|
|
|
|
3SBio, Inc. - ADR (a) |
|
|
79,100 |
|
$ |
1,273,510 |
|
Achillion Pharmaceuticals, Inc. (a) |
|
|
41,600 |
|
|
308,256 |
|
Acorda Therapeutics, Inc. (a) |
|
|
118,000 |
|
|
3,351,200 |
|
Alexion Pharmaceuticals, Inc. (a) |
|
|
62,424 |
|
|
3,545,683 |
|
Amgen, Inc. |
|
|
94,700 |
|
|
5,180,090 |
|
Ariad Pharmaceuticals, Inc. (a) |
|
|
50,000 |
|
|
594,500 |
|
Biogen Idec, Inc. (a) |
|
|
54,200 |
|
|
5,521,354 |
|
BioMarin Pharmaceutical, Inc. (a) |
|
|
43,200 |
|
|
1,349,136 |
|
Celgene Corp. (a) |
|
|
99,200 |
|
|
5,882,560 |
|
Gilead Sciences, Inc. (a) |
|
|
127,400 |
|
|
5,396,664 |
|
Human Genome Sciences, Inc. (a) |
|
|
130,600 |
|
|
2,743,906 |
|
Momenta Pharmaceutical, Inc. (a) |
|
|
75,700 |
|
|
1,336,862 |
|
NPS Pharmaceuticals, Inc. (a) |
|
|
114,700 |
|
|
1,108,002 |
|
Rigel Pharmaceuticals, Inc. (a) |
|
|
23,000 |
|
|
199,870 |
|
United Therapeutics Corp. (a) |
|
|
32,900 |
|
|
1,887,802 |
|
Vertex Pharmaceuticals, Inc. (a) |
|
|
43,941 |
|
|
2,278,781 |
|
|
|
|
|
|
|
41,958,176 |
|
Diversified Consumer Services 0.3% |
|
|
|
|
|
|
|
Stewart Enterprises, Inc., Class A |
|
|
108,100 |
|
|
751,295 |
|
Health Care Equipment & Supplies 19.1% |
|
|
|
|
|
|
|
Baxter International, Inc. |
|
|
140,200 |
|
|
8,155,434 |
|
C.R. Bard, Inc. |
|
|
21,200 |
|
|
2,092,016 |
|
China Kanghui Holdings, Inc. - ADR (a) |
|
|
12,600 |
|
|
274,554 |
|
The Cooper Cos., Inc. |
|
|
83,400 |
|
|
6,379,266 |
|
Covidien Plc |
|
|
91,400 |
|
|
4,642,206 |
|
DENTSPLY International, Inc. |
|
|
58,600 |
|
|
2,220,354 |
|
GN Store Nord A/S |
|
|
88,900 |
|
|
804,550 |
|
Hill-Rom Holdings, Inc. |
|
|
84,300 |
|
|
3,143,547 |
|
Hologic, Inc. (a) |
|
|
350,400 |
|
|
6,506,928 |
|
Masimo Corp. |
|
|
47,100 |
|
|
1,308,438 |
|
Medtronic, Inc. |
|
|
97,200 |
|
|
3,504,060 |
|
Mindray Medical International |
|
|
99,100 |
|
|
2,683,628 |
|
Nobel Biocare Holding AG |
|
|
30,600 |
|
|
585,387 |
|
Sirona Dental Systems, Inc. (a) |
|
|
17,000 |
|
|
859,860 |
|
Smith & Nephew Plc |
|
|
116,400 |
|
|
1,224,464 |
|
St. Jude Medical, Inc. |
|
|
108,700 |
|
|
5,054,550 |
|
Stryker Corp. |
|
|
54,600 |
|
|
2,966,964 |
|
Teleflex, Inc. |
|
|
15,000 |
|
|
903,450 |
|
Wright Medical Group, Inc. (a)(b) |
|
|
78,900 |
|
|
1,233,996 |
|
Zimmer Holdings, Inc. (a) |
|
|
28,100 |
|
|
1,686,562 |
|
|
|
|
|
|
|
56,230,214 |
|
Health Care Providers & Services 30.1% |
|
|
|
|
|
|
|
Aetna, Inc. |
|
|
207,800 |
|
|
8,621,622 |
|
AmerisourceBergen Corp. |
|
|
164,300 |
|
|
6,294,333 |
|
CIGNA Corp. |
|
|
38,100 |
|
|
1,896,237 |
|
Cardinal Health, Inc. |
|
|
188,600 |
|
|
8,253,136 |
|
DaVita, Inc. (a) |
|
|
94,000 |
|
|
7,852,760 |
|
Express Scripts, Inc. (a) |
|
|
59,800 |
|
|
3,244,748 |
|
|
|
|
|
|
|
|
|
Common Stocks |
|
|
Shares |
|
|
Value |
|
Health Care Providers & Services (concluded) |
|
|
|
|
|
|
|
Fresenius Medical Care AG & Co. |
|
|
73,200 |
|
$ |
5,617,872 |
|
Henry Schein, Inc. (a) |
|
|
116,600 |
|
|
7,749,236 |
|
Humana, Inc. |
|
|
39,700 |
|
|
2,960,826 |
|
Laboratory Corp. of America |
|
|
75,400 |
|
|
6,843,304 |
|
McKesson Corp. |
|
|
89,100 |
|
|
7,227,792 |
|
Medco Health Solutions, Inc. (a) |
|
|
137,100 |
|
|
8,620,848 |
|
Patterson Cos., Inc. |
|
|
27,800 |
|
|
857,352 |
|
UnitedHealth Group, Inc. |
|
|
215,700 |
|
|
10,705,191 |
|
WellPoint, Inc. |
|
|
31,533 |
|
|
2,130,054 |
|
|
|
|
|
|
|
88,875,311 |
|
Life Sciences Tools & Services 2.9% |
|
|
|
|
|
|
|
Agilent Technologies, Inc. (a) |
|
|
54,400 |
|
|
2,293,504 |
|
Life Technologies Corp. (a) |
|
|
84,000 |
|
|
3,782,520 |
|
ShangPharma Corp. - ADR (a) |
|
|
30,600 |
|
|
361,080 |
|
Thermo Fisher Scientific, Inc. (a) |
|
|
36,600 |
|
|
2,199,294 |
|
|
|
|
|
|
|
8,636,398 |
|
Machinery 1.4% |
|
|
|
|
|
|
|
Pall Corp. |
|
|
85,100 |
|
|
4,219,258 |
|
Pharmaceuticals 25.3% |
|
|
|
|
|
|
|
Abbott Laboratories |
|
|
82,200 |
|
|
4,218,504 |
|
Allergan, Inc. |
|
|
128,600 |
|
|
10,456,466 |
|
Auxilium Pharmaceuticals, Inc. (a) |
|
|
39,500 |
|
|
740,230 |
|
Bristol-Myers Squibb Co. |
|
|
214,800 |
|
|
6,156,168 |
|
Elan Corp. Plc - ADR (a) |
|
|
175,700 |
|
|
1,943,242 |
|
Eli Lilly & Co. |
|
|
55,400 |
|
|
2,121,820 |
|
Forest Laboratories, Inc. (a) |
|
|
84,900 |
|
|
3,146,394 |
|
GlaxoSmithKline Plc |
|
|
51,600 |
|
|
1,150,429 |
|
GlaxoSmithKline Plc - ADR |
|
|
17,000 |
|
|
755,140 |
|
Hospira, Inc. (a) |
|
|
71,100 |
|
|
3,634,632 |
|
Ironwood Pharmaceuticals, Inc. (a) |
|
|
50,200 |
|
|
750,490 |
|
Johnson & Johnson |
|
|
120,500 |
|
|
7,807,195 |
|
Merck & Co., Inc. |
|
|
178,500 |
|
|
6,092,205 |
|
Merck KGaA |
|
|
23,800 |
|
|
2,540,074 |
|
Pfizer, Inc. |
|
|
523,300 |
|
|
10,068,292 |
|
Roche Holding AG |
|
|
22,800 |
|
|
4,091,365 |
|
Shire Plc - ADR |
|
|
32,200 |
|
|
3,348,800 |
|
Watson Pharmaceuticals, Inc. (a) |
|
|
81,500 |
|
|
5,471,095 |
|
|
|
|
|
|
|
74,492,541 |
|
Total
Long-Term Investments |
|
|
|
|
|
275,163,193 |
|
|
|
|
|
|
|
|
|
|
|
Portfolio Abbreviations |
To simplify the listings of portfolio holdings in the Schedule of Investments, the names and descriptions of many of the securities have been abbreviated according to the following list:
|
|
ADR |
American Depositary Receipts |
CHF |
Swiss Franc |
DKK |
Danish Krone |
EUR |
Euro |
GBP |
British Pound |
USD |
US Dollar |
|
|
|
|
|
|
|
|
|
|
|
|
|
BLACKROCK HEALTHCARE FUND, INC. |
JULY 31, 2011 |
1 |
|
|
|
|
Schedule of Investments (continued) |
BlackRock Healthcare Fund, Inc. |
|
(Percentages shown are based on Net Assets) |
|
|
|
|
|
|
|
|
Short-Term Securities |
|
Shares |
|
Value |
|
||
BlackRock Liquidity Funds, |
|
|
18,088,460 |
|
$ |
18,088,460 |
|
|
|
|
|
|
|
|
|
|
|
|
Beneficial
|
|
|
|
|
BlackRock Liquidity Series, LLC |
|
$ |
1,363 |
|
|
1,362,501 |
|
Total
Short-Term Securities |
|
|
|
|
|
19,450,961 |
|
Total
Investments Before Outstanding Options |
|
|
|
|
|
294,614,154 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Written |
|
Contracts |
|
|
|
|
|
Exchange-Traded Call |
|
|
|
|
|
|
|
AmerisourceBergen Corp., Strike |
|
|
820 |
|
|
(59,450 |
) |
Medco Health Solutions, Inc., Strike |
|
|
69 |
|
|
(74,543 |
) |
UnitedHealth Group, Inc., Strike Price |
|
|
215 |
|
|
(25,800 |
) |
|
|
|
|
|
|
(159,793 |
) |
Exchange-Traded Put |
|
|
|
|
|
|
|
AmerisourceBergen Corp., Strike |
|
|
397 |
|
|
(39,700 |
) |
Total
Options Written |
|
|
|
|
|
(199,493 |
) |
Total
Investments, Net of Outstanding Options |
|
|
|
|
|
294,414,661 |
|
Other Assets Less Liabilities 0.2% |
|
|
|
|
|
493,749 |
|
Net Assets 100.0% |
|
|
|
|
$ |
294,908,410 |
|
|
|
* |
The cost and unrealized appreciation (depreciation) of investments as of July 31, 2011, as computed for federal income tax purposes, were as follows: |
|
|
|
|
|
Aggregate cost |
|
$ |
274,126,590 |
|
Gross unrealized appreciation |
|
$ |
30,601,519 |
|
Gross unrealized depreciation |
|
|
(10,113,955 |
) |
Net unrealized appreciation |
|
$ |
20,487,564 |
|
|
|
(a) |
Non-income producing security. |
|
|
(b) |
Security, or a portion of security, is on loan. |
|
|
(c) |
Investments in companies considered to be an affiliate of the Fund during the period, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Affiliate |
|
Shares/ |
|
Net Activity |
|
Shares/ |
|
Income |
|
||||
BlackRock Liquidity Funds, TempCash, Institutional Class |
|
|
18,370,482 |
|
|
(282,022 |
) |
|
18,088,460 |
|
$ |
3,584 |
|
BlackRock Liquidity Series, LLC Money Market Series |
|
$ |
468,000 |
|
$ |
894,501 |
|
$ |
1,362,501 |
|
$ |
1,827 |
|
|
|
(d) |
Represents the current yield as of report date. |
|
|
(e) |
Security was purchased with the cash collateral from loaned securities. |
|
|
|
For Fund compliance purposes, the Funds industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by Fund management. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of Investments (concluded) |
BlackRock Healthcare Fund, Inc. |
|
|
|
Foreign currency exchange contracts as of July 31, 2011 were as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Currency |
|
|
|
Settlement |
Unrealized |
|
||
Purchased |
|
Currency Sold |
Counterparty |
Date |
(Depreciation) |
|
||
CHF |
29,000 USD |
|
36,182 |
UBS AG |
8/02/11 |
$ |
664 |
|
EUR |
738,000 USD |
|
1,045,642 |
Citibank NA |
10/07/11 |
|
13,121 |
|
GBP |
95,000 USD |
|
153,251 |
Citibank NA |
10/07/11 |
|
2,578 |
|
USD |
4,389,986 CHF |
|
3,676,000 |
Citibank NA |
10/07/11 |
|
(285,156 |
) |
USD |
36,202 CHF |
|
29,000 |
UBS AG |
10/07/11 |
|
(680 |
) |
|
|
|
|
Deutsche |
|
|
|
|
USD |
785,289 DKK |
|
4,100,000 |
Securities Inc. |
10/07/11 |
|
(4,262 |
) |
USD |
212,600 EUR |
|
150,000 |
Citibank NA |
10/07/11 |
|
(2,596 |
) |
|
|
|
|
Deutsche |
|
|
|
|
USD |
9,204,621 EUR |
|
6,446,000 |
Securities Inc. |
10/07/11 |
|
(43,059 |
) |
USD |
2,385,336 GBP |
|
1,492,000 |
Citibank NA |
10/07/11 |
|
(61,996 |
) |
Total |
|
$ |
(381,386 |
) |
|
|
|
|
|
|
Fair Value Measurements - Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs are categorized in three broad levels for financial reporting purposes as follows: |
|
|
|
|
|
|
|
|
Level 1 price quotations in active markets/exchanges for identical assets and liabilities |
|
|
|
|
|
|
|
Level 2 other observable inputs (including, but not limited to: quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs) |
|
|
|
|
|
|
|
Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Funds own assumptions used in determining the fair value of investments and derivative financial instruments) |
The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and does not necessarily correspond to the Funds perceived risk of investing in those securities. For information about the Funds policy regarding valuation of investments and derivative financial instruments and other significant accounting policies please refer to the Funds most recent financial statements as contained in its annual report.
The following tables summarize the inputs used as of July 31, 2011 in determining the fair valuation of the Funds investments and derivative financial instruments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Valuation Inputs |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
|
||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term Investments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stocks: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology |
|
$ |
41,958,176 |
|
|
|
|
|
|
|
$ |
41,958,176 |
|
Diversified Consumer Services |
|
|
751,295 |
|
|
|
|
|
|
|
|
751,295 |
|
Health Care Equipment & Supplies |
|
|
53,615,813 |
|
$ |
2,614,401 |
|
|
|
|
|
56,230,214 |
|
Health Care Providers & Services |
|
|
83,257,439 |
|
|
5,617,872 |
|
|
|
|
|
88,875,311 |
|
Life Sciences Tools & Services |
|
|
8,636,398 |
|
|
|
|
|
|
|
|
8,636,398 |
|
Machinery |
|
|
4,219,258 |
|
|
|
|
|
|
|
|
4,219,258 |
|
Pharmaceuticals |
|
|
66,710,673 |
|
|
7,781,868 |
|
|
|
|
|
74,492,541 |
|
Short-Term Securities |
|
|
18,088,460 |
|
|
1,362,501 |
|
|
|
|
|
19,450,961 |
|
Total |
|
$ |
277,237,512 |
|
$ |
17,376,642 |
|
|
|
|
$ |
294,614,154 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Valuation Inputs |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
|
||||
Derivative Financial Instruments1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency |
|
|
|
|
$ |
16,363 |
|
|
|
|
$ |
16,363 |
|
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency |
|
|
|
|
|
(397,749 |
) |
|
|
|
|
(397,749 |
) |
Equity contracts |
|
$ |
(124,950 |
) |
|
(74,543 |
) |
|
|
|
|
(199,493 |
) |
Total |
|
$ |
(124,950 |
) |
$ |
(455,929 |
) |
|
|
|
$ |
(580,879 |
) |
|
|
|
|
1 |
Derivative financial instruments are foreign currency exchange contracts and options. Foreign currency exchange contracts are valued at the unrealized appreciation/depreciation on the instrument and options are shown at value. |
|
|
Effective
September 12, 2011, the Fund merged into BlackRock |
|
|
|
|
|
|
|
|
|
Item 2 – |
Controls and Procedures |
||
|
|
||
2(a) – |
The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”)) are effective as of a date within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 15d-15(b) under the Securities Exchange Act of 1934, as amended. |
||
|
|
||
2(b) – |
There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the registrant’s last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
||
|
|
||
Item 3 – |
Exhibits |
||
|
|
||
|
Certifications – Attached hereto |
||
|
|
||
|
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
||
|
|
||
|
BlackRock Healthcare Fund, Inc. |
||
|
|
||
|
By: | /s/ John M. Perlowski |
|
|
|
John M. Perlowski |
|
|
|
Chief Executive Officer (principal executive officer) of |
|
|
|
BlackRock Healthcare Fund, Inc. |
|
|
|
||
|
Date: September 26, 2011 |
||
|
|
||
|
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. |
||
|
|
||
|
By: | /s/ John M. Perlowski |
|
|
|
John M. Perlowski |
|
|
|
Chief Executive Officer (principal executive officer) of |
|
|
|
BlackRock Healthcare Fund, Inc. |
|
|
|
||
|
Date: September 26, 2011 |
||
|
|
||
|
By: | /s/ Neal J. Andrews |
|
|
|
Neal J. Andrews |
|
|
|
Chief Financial Officer (principal financial officer) of |
|
|
|
BlackRock Healthcare Fund, Inc. |
|
|
|
|
|
|
Date: September 26, 2011 |
EX-99. CERT
CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Healthcare Fund, Inc., certify that:
1. I have reviewed this report on Form N-Q of BlackRock Healthcare Fund, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the schedules of investments included in this report fairly present in all material respects the investments of the registrant as of the end of the fiscal quarter for which the report is filed;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report, based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: September 26, 2011
/s/ John M. Perlowski |
|
John M. Perlowski
Chief Executive Officer (principal executive officer) of
BlackRock Healthcare Fund, Inc.
EX-99. CERT
CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Neal J. Andrews, Chief Financial Officer (principal financial officer) of BlackRock Healthcare Fund, Inc., certify that:
1. I have reviewed this report on Form N-Q of BlackRock Healthcare Fund, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the schedules of investments included in this report fairly present in all material respects the investments of the registrant as of the end of the fiscal quarter for which the report is filed;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report, based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: September 26, 2011
/s/ Neal J. Andrews |
|
Neal J. Andrews
Chief Financial Officer (principal financial officer) of
BlackRock Healthcare Fund, Inc.